- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07592806
CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation (CRISTEL)
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
According to North American and Australian registries, pregnancy is both a joyful and high-risk event for women who have received a solid organ transplant. Typically, a transplanted woman has a probability comparable to that of the general population of giving birth to a live infant, but she is likely to deliver prematurely (median gestational age: 32 weeks), to have a growth-restricted baby (median birth weight around 2.3 kg), and often in a context of preeclampsia (in at least 30% of cases)(1).
Today, these are the data shared with patients planning a pregnancy, despite uncertainty as to their accuracy and applicability in France or even Europe.
Among the unknowns that remain despite these registry data, the following should be noted:
Uncertainty about the level of pregnancy planning in this specific context: What proportion of women of childbearing age have been informed of the possibility of becoming pregnant, of the associated risks, and of necessary precautions (e.g., stopping mycophenolate mofetil at least 6 weeks before conception);
Variability in the information provided from one center to another, due to the absence of a national, consensus-based document addressing fertility and contraception in the post-transplantation setting;
Monitoring frequency specific to the graft, especially regarding exposure to immunosuppressive drugs (and consequently actual exposure to calcineurin inhibitors, the cornerstone of anti-rejection therapy, whose residual blood concentration varies from the second trimester onward)(2);
The true risk of preeclampsia, at a time when diagnosis can be refined by measuring levels of placental-derived anti-angiogenic factors in maternal serum (sFlt-1/PlGF ratio)(3), and by uterine artery Doppler;
The incidence of de novo anti-HLA immunization (HLA antigens expressed by the fetus and inherited from the father), which can now be assessed using the Luminex technique(4);
Maternal morbidity: What is the impact of pregnancy on graft function? Conversely, how does renal function influence pregnancy outcomes, regardless of the transplanted organ?
Infant morbidity in the short and medium term.
To establish these data and to provide accurate information to patients, we aim to conduct a study among pregnant women who have undergone solid organ transplantation (kidney, heart, lung, liver, or pancreas). The objective of this research is to collect standardized and independent data on the number of pregnancies occurring in France and to monitor them up to one year postpartum (or after pregnancy termination).
The study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will help disseminate clear and up-to-date information to the medical community, thus improving patient counseling and, more broadly, support for couples. They will also serve to develop recommendations to optimize the planning and management of pregnancies in women with solid organ transplants.
Finally, this initiative aims to promote clinical research on pregnancy in the context of transplantation, particularly through clinical trials and the development of biobanks.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Sahar Pr SELLAMI JALLOULI, PhD
- Telefoonnummer: 01 46 25 31 37
- E-mail: s.sellami-jallouli@hopital-foch.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Female patient aged 18 years or older and of childbearing age
- Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney)
- Has a positive blood beta-hCG test result > 5 IU/L ("positive")
- Has signed an informed consent form
- Affiliated with a health insurance plan
Exclusion Criteria:
- Patient deprived of liberty or under legal guardianship
- Patient refuses to participate in the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Screening
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Adult female patients who have received a solid organ transplant
Adult female patients who have received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney), and who present with a positive beta-hCG blood test result (defined by a threshold of 5 IU/L) in one of the participating centers, or who are planning a pregnancy, will initially be identified.
|
Two optional (non-mandatory) biological samples may be collected as part of this study: A 2 mL venous blood sample may be taken during a routine prenatal follow-up visit (around 30 weeks of gestation) in order to analyze the preeclampsia biomarker (sFlt-1/PlGF ratio), whenever preeclampsia is suspected. A 5 mL sample from cord blood may be collected after delivery to analyze, in the newborn, the complete blood count, white blood cell differential, lymphocyte phenotyping (T CD3+, CD19+CD20+, and NK CD46+), and immunoglobulin levels (G, A, and M for humoral immunity, and E for allergy-related function). |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
Tijdsspanne: Annually over the 10-year study period
|
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
|
Annually over the 10-year study period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Rate of preeclampsia
Tijdsspanne: Through study completion, an average of 1 year
|
Rate of preeclampsia
|
Through study completion, an average of 1 year
|
|
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
Tijdsspanne: 3 months and 12 months postopartum
|
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73
m²);
|
3 months and 12 months postopartum
|
|
Live birth rate among transplanted mothers from the onset of pregnancy.
Tijdsspanne: through study completion, an average of 1 year
|
Live birth rate among transplanted mothers from the onset of pregnancy.
|
through study completion, an average of 1 year
|
|
Trajectory of serum creatinine levels
Tijdsspanne: During pregnancy (up to 40 weeks if gestation)
|
Trajectory of serum creatinine levels
|
During pregnancy (up to 40 weeks if gestation)
|
|
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
Tijdsspanne: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
|
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
|
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
|
|
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
Tijdsspanne: Day of delivery: Perioperative/Periprocedural
|
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
|
Day of delivery: Perioperative/Periprocedural
|
|
Birth weight of the newborn (in grams)
Tijdsspanne: day of delivery
|
Birth weight of the newborn (in grams)
|
day of delivery
|
|
Rate of spontaneous miscarriage
Tijdsspanne: Through study completion, an average of 1 year
|
Rate of spontaneous miscarriage
|
Through study completion, an average of 1 year
|
|
Rate of cesarean section
Tijdsspanne: Through study completion, an average of 1 year
|
Rate of cesarean section
|
Through study completion, an average of 1 year
|
|
Rate of prematurity
Tijdsspanne: Through study completion, an average of 1 year
|
Rate of prematurity
|
Through study completion, an average of 1 year
|
|
Rate of intrauterine growth restriction
Tijdsspanne: Through study completion, an average of 1 year
|
Rate of intrauterine growth restriction
|
Through study completion, an average of 1 year
|
|
the duration of hospital stay for both the mother and the newborn
Tijdsspanne: Through study completion, an average of 1 year
|
the duration of hospital stay for both the mother and the newborn
|
Through study completion, an average of 1 year
|
|
incidence of biopsy-proven acute rejection up to 12 months postpartum;
Tijdsspanne: up to 12 months postpartum;
|
incidence of biopsy-proven acute rejection up to 12 months postpartum;
|
up to 12 months postpartum;
|
|
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
Tijdsspanne: 3 months and 12 months postoartum
|
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
|
3 months and 12 months postoartum
|
|
Trajectory of proteinuria (protein-to-creatinine ratio)
Tijdsspanne: During pregnancy (up to 40 weeks if gestation)
|
Trajectory of proteinuria (protein-to-creatinine ratio)
|
During pregnancy (up to 40 weeks if gestation)
|
|
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
Tijdsspanne: During pregnancy (up to 40 weeks if gestation)
|
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
|
During pregnancy (up to 40 weeks if gestation)
|
|
Trajectory of anti-angiogenic factors during pregnancy
Tijdsspanne: During pregnancy (up to 40 weeks if gestation)
|
Trajectory of anti-angiogenic factors during pregnancy
|
During pregnancy (up to 40 weeks if gestation)
|
|
Rate of maternal complications and hospitalizations before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
Tijdsspanne: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
|
Rate of maternal hospitalizations before delivery and in the postpartum period
|
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
|
|
Apgar score
Tijdsspanne: day of delivery
|
Apgar score
|
day of delivery
|
|
Proportion of growth-restricted
Tijdsspanne: day of delivery and up 3 month postpartum
|
Proportion of growth-restricted
|
day of delivery and up 3 month postpartum
|
|
Incidence of neonatal complications before the third month of life
Tijdsspanne: day of delivery and up 3 month postpartum
|
Incidence of neonatal complications before the third month of life
|
day of delivery and up 3 month postpartum
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Alexandre Pr Hertig, MED, Foch Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2023_0004
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .